Asset icon - trade crypto, stocks, and gold on Pluang
Trade on Pluang
One platform for all markets
Download
Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Adecoagro SA (AGRO) vs Novavax Inc (NVAX) Price & Performance

Adecoagro SA
Novavax Inc

Price performance

Price movement over the last 24 hours

Key statistics

Adecoagro SA vs Novavax Inc — how do they compare? Adecoagro SA trades at $10.23 (market cap $1.39B), while Novavax Inc trades at $9.33 (market cap $1.56B). The key difference: Adecoagro SA and Novavax Inc are close in size by market cap, and Adecoagro SA pays a 3.08% dividend while Novavax Inc pays none. Which is the better fit depends on your goals.

AGRONVAX
Market Cap
$1.39B$1.56B
Sector
TechnologyHealth
52-Week High
$15.25$11.19
52-Week Low
$7.13$6.22
Enterprise Value
$3.42B$1.06B
Dividend Yield
3.08%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Adecoagro SA

AGRO trades at $9.48, down 1.66% today, with a bearish technical signal despite neutral oscillators. The company reported mixed quarterly results, missing Q1 2026 EPS estimates but showing strong adjusted EBITDA growth. Valuation metrics appear attractive with P/S of 0.71 and P/B of 0.78, though profitability remains weak with a 0.91% net margin. Recent news highlights innovation in agriculture operations and a declared $0.12 dividend for H1 2026.

The stock offers value appeal with below-market multiples and analyst consensus target of $12.75 implying 34% upside. However, inconsistent earnings performance and negative net income in 2025 pose execution risks. The bearish technical trend and competitive pressures in sustainable agriculture require careful monitoring for potential investors.

Novavax Inc

Novavax (NVAX) trades at $9.46, down 2.87% on the day, with a bullish technical signal from moving averages. The company reported strong revenue of $1.12B in 2025 and has beaten EPS estimates for three consecutive quarters. Analyst consensus is bullish with a $14.00 price target, though negative cash flow and shareholder equity remain concerns. Recent news highlights investor attention and participation in healthcare conferences.

Outlook: Potential upside exists from continued earnings beats and vaccine demand, but risks include persistent cash burn, high debt, and competitive pressures. The stock offers speculative growth opportunity amid volatile biotech sentiment, requiring careful risk assessment.

Returns comparison

Trailing returns across standard periods

About Adecoagro SA

Adecoagro is a South American agricultural company. It operates a diversified business including farming crops, rice, and dairy, as well as producing sugar, ethanol, and renewable energy from its industrial facilities.

Read more on AGRO

About Novavax Inc

Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.

Read more on NVAX